Key terms
About DBVT
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest DBVT news
Mar 08
4:24pm ET
DBV Technologies Announces Completion of Annual Report
Mar 08
6:29am ET
Buy Rating Affirmed for DBV Technologies on Viaskin Patch Development and Positive Trial Outcomes
Mar 08
12:26am ET
Positive Clinical and Financial Projections for DBV Technologies Reinforce Buy Rating
Feb 26
12:25am ET
Buy Rating Affirmed for DBV Technologies on Strong Viaskin Peanut Patch Clinical Data and Promising Trials
Feb 20
12:45am ET
JMP Securities Keeps Their Buy Rating on DBV Technologies SA – American (DBVT)
Feb 16
3:35pm ET
Buy Rating for DBV Technologies: Viaskin Peanut’s Market Edge Over Xolair
Jan 22
1:17pm ET
Buy Rating Affirmed for DBV Technologies Amid Reduced Competition and Promising Clinical Progress
No recent press releases are available for DBVT
DBVT Financials
Key terms
Ad Feedback
DBVT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
DBVT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
